Peter van Mourik

198 Chapter 9 31. Wainwright, C. E. et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N. Engl. J. Med. 1–12 (2015) doi:10.1056/ NEJMoa1409547. 32. Taylor-Cousar, J. L. et al. Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N. Engl. J. Med. NEJMoa1709846 (2017) doi:10.1056/NEJMoa1709846. 33. Rowe, S. M. et al. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR. Ann. Am. Thorac. Soc. 14 , 213–219 (2017). 34. Van Goor, F. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. 108 , 18843– 18848 (2011). 35. Okiyoneda, T. et al. Mechanism-based corrector combination restores D F508- CFTR folding and function. Nat. Chem. Biol. 9 , 444–454 (2013). 36. Heijerman, H. G. M. et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet (London, England) 6736 , 6–14 (2019). 37. Middleton, P. G. et al. Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N. Engl. J. Med. 381 , 1809–1819 (2019). 38. National Health Service. NHS England concludes wide-ranging deal for cystic fibrosis drugs. https://www.england.nhs.uk/2019/10/nhs-england-concludes- wide-ranging-deal-for-cystic-fibrosis-drugs/. 39. Zorginstituut Nederland. Lumacaftor/ivacaftor (Orkambi®) bij cystische fibrose (CF). 2016-2017 (2017). 40. Dekkers, J. F. et al. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Eur. Respir. J. 48 , 451–8 (2016). 41. Van Mourik, P. et al. R117H-CFTR function and response to VX-770 correlate with mRNA and protein expression in intestinal organoids. J. Cyst. Fibros. (2020) doi:10.1016/j.jcf.2020.02.001. 42. Shteinberg, M. et al. Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His . ERJ Open Res. 3 , 00056–02016 (2017). 43. Wagener, J. S. et al. Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation. J. Cyst. Fibros. (2017) doi:10.1016/j.jcf.2017.10.003. 44. Massie, R. J. H. et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur. Respir. J. 17 , 1195–1200 (2001). 45. O’Sullivan, B. P., Zwerdling, R. G., Dorkin, H. L., Comeau, A. M. & Parad, R. Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/ R117H-7T genotype. Pediatrics 118 , 1260–5 (2006). 46. Moss, R. B. et al. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: A double-blind, randomised controlled trial. Lancet Respir. Med. 3 , 524–533 (2015).